

Massimo Degan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/46088/publications.pdf>

Version: 2024-02-01

70
papers

2,549
citations

218592

26
h-index

206029

48
g-index

70
all docs

70
docs citations

70
times ranked

2786
citing authors

#	ARTICLE	IF	CITATIONS
1	Gene expression in regenerating and scarring tails of lizard evidences three main key genes (wnt2b,) Tj ETQq1 1 0.784314 rgBT /Over bo 258, 3-17.	1.0	15
2	<i>TP53</i> Mutations with Low Variant Allele Frequency Predict Short Survival in Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2021, 27, 5566-5575.	3.2	23
3	Quality Assessment for PCR-based Minimal Residual Disease in Lymphoma: 10 Years of Cross-laboratory Standardization Process Within the Fondazione Italiana Linfomi MRD Network. <i>HemaSphere</i> , 2021, 5, e639.	1.2	0
4	A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia. <i>Haematologica</i> , 2020, 105, 1613-1620.	1.7	15
5	Minimal residual disease (MRD) in non-Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD Network. <i>Hematological Oncology</i> , 2019, 37, 368-374.	0.8	13
6	A B-cell receptor-related gene signature predicts response to ibrutinib treatment in mantle cell lymphoma cell lines. <i>Haematologica</i> , 2019, 104, e410-e414.	1.7	5
7	Transcriptomics and Immunological Analyses Reveal a Pro-Angiogenic and Anti-Inflammatory Phenotype for Decidual Endothelial Cells. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1604.	1.8	9
8	<i>NOTCH1</i> mutational status in chronic lymphocytic leukaemia: clinical relevance of subclonal mutations and mutation types. <i>British Journal of Haematology</i> , 2018, 182, 597-602.	1.2	22
9	Mutations in the 3' untranslated region of <i>NOTCH1</i> are associated with low CD20 expression levels chronic lymphocytic leukemia. <i>Haematologica</i> , 2017, 102, e305-e309.	1.7	18
10	NOTCH1-mutated chronic lymphocytic leukemia cells are characterized by a MYC-related overexpression of nucleophosmin 1 and ribosome-associated components. <i>Leukemia</i> , 2017, 31, 2407-2415.	3.3	52
11	Mutational status of <i>IGHV</i> is the most reliable prognostic marker in trisomy 12 chronic lymphocytic leukemia. <i>Haematologica</i> , 2017, 102, e443-e446.	1.7	11
12	CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia. <i>Leukemia</i> , 2016, 30, 2011-2018.	3.3	41
13	NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation. <i>Leukemia</i> , 2016, 30, 182-189.	3.3	74
14	Clinical significance of c.7544-7545 delCT <i>NOTCH1</i> mutation in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2013, 160, 415-418.	1.2	14
15	Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application. <i>Journal of Hematology and Oncology</i> , 2013, 6, 83.	6.9	14
16	<i>ARHGDI3</i> , a mutant <i>TP53</i> -associated Rho GDP dissociation inhibitor, is overexpressed in gene expression profiles of <i>TP53</i> disrupted chronic lymphocytic leukaemia cells. <i>British Journal of Haematology</i> , 2013, 161, 596-599.	1.2	3
17	Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia. <i>Blood</i> , 2013, 121, 4902-4905.	0.6	113
18	<i>IGHD3</i> fails to behave as unfavourable prognostic marker in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2010, 149, 299-302.	1.2	1

#	ARTICLE	IF	CITATIONS
19	<i>MDM4 (MDMX)</i> is overexpressed in chronic lymphocytic leukaemia (CLL) and marks a subset of p53 ^{wild-type} CLL with a poor cytotoxic response to Nutlin-3. <i>British Journal of Haematology</i> , 2010, 150, 237-239.	1.2	27
20	Expression of Mutated <i>IGHV3-23</i> Genes in Chronic Lymphocytic Leukemia Identifies a Disease Subset with Peculiar Clinical and Biological Features. <i>Clinical Cancer Research</i> , 2010, 16, 620-628.	3.2	44
21	Prognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: mean fluorescence intensity T/B ratio versus percentage of positive cells. <i>Journal of Translational Medicine</i> , 2010, 8, 23.	1.8	19
22	CD38/CD31, the CCL3 and CCL4 Chemokines, and CD49d/Vascular Cell Adhesion Molecule-1 Are Interchained by Sequential Events Sustaining Chronic Lymphocytic Leukemia Cell Survival. <i>Cancer Research</i> , 2009, 69, 4001-4009.	0.4	153
23	Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study. <i>British Journal of Haematology</i> , 2009, 144, 492-506.	1.2	106
24	Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. <i>Cancer</i> , 2008, 112, 119-128.	2.0	86
25	Are surrogates of IGHV gene mutational status useful in B-cell chronic lymphocytic leukemia? The example of Septin-10. <i>Leukemia</i> , 2008, 22, 224-226.	3.3	8
26	Preclinical ex vivo expansion of peripheral blood CD34+ selected cells from cancer patients mobilized with combination chemotherapy and granulocyte colony-stimulating factor. <i>Vox Sanguinis</i> , 2008, 94, 342-350.	0.7	5
27	Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. <i>Blood</i> , 2008, 111, 865-873.	0.6	226
28	Comprehensive characterization of IGHV3-21-expressing B-cell chronic lymphocytic leukemia: an Italian multicenter study. <i>Blood</i> , 2007, 109, 2989-2998.	0.6	62
29	Laminin-332 (Laminin-5) is the major motility ligand for B cell chronic lymphocytic leukemia. <i>Matrix Biology</i> , 2007, 26, 473-484.	1.5	11
30	Telomerase expression in B-cell chronic lymphocytic leukemia predicts survival and delineates subgroups of patients with the same IgVH mutation status and different outcome. <i>Leukemia</i> , 2007, 21, 965-972.	3.3	57
31	Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. <i>Blood</i> , 2006, 108, 853-861.	0.6	171
32	Surface-antigen expression profiling of B cell chronic lymphocytic leukemia: from the signature of specific disease subsets to the identification of markers with prognostic relevance. <i>Journal of Translational Medicine</i> , 2006, 4, 11.	1.8	9
33	Concomitant chronic lymphocytic leukemia and acute myeloid leukemia: Evidence of simultaneous expansion of two independent clones. <i>Leukemia and Lymphoma</i> , 2006, 47, 885-889.	0.6	18
34	CD49d in B-cell chronic lymphocytic leukemia: correlated expression with CD38 and prognostic relevance. <i>Leukemia</i> , 2006, 20, 523-525.	3.3	51
35	Reply to Pittner et al.. <i>Leukemia</i> , 2006, 20, 528-529.	3.3	10
36	Immunophenotypic characterization of IgVH3-72 B-cell chronic lymphocytic leukaemia (B-CLL). <i>Leukemia Research</i> , 2006, 30, 1197-1199.	0.4	17

#	ARTICLE	IF	CITATIONS
37	ZAP-70 expression in B-cell chronic lymphocytic leukemia: Evaluation by external (isotypic) or internal (T/NK cells) controls and correlation with IgVH mutations. <i>Cytometry Part B - Clinical Cytometry</i> , 2006, 70B, 284-292.	0.7	38
38	A scoring system based on the expression of six surface molecules allows the identification of three prognostic risk groups in B-cell chronic lymphocytic leukemia. <i>Journal of Cellular Physiology</i> , 2006, 207, 354-363.	2.0	49
39	Mutational status of IgVH genes in B-cell chronic lymphocytic leukemia and prognosis: percent mutations or antigen-driven selection?. <i>Leukemia</i> , 2005, 19, 1490-1492.	3.3	23
40	Epigenetic Immunomodulation of Hematopoietic Malignancies. <i>Seminars in Oncology</i> , 2005, 32, 503-510.	0.8	17
41	Surface-antigen expression profiling (SEP) in B-cell chronic lymphocytic leukemia (B-CLL): Identification of markers with prognostic relevance. <i>Journal of Immunological Methods</i> , 2005, 305, 20-32.	0.6	17
42	Signature of B-CLL with different prognosis by Shrunken centroids of surface antigen expression profiling. <i>Journal of Cellular Physiology</i> , 2005, 204, 113-123.	2.0	30
43	Activation-Induced Cytidine Deaminase and CD38 Expression in B-Cell Chronic Lymphocytic Leukemia. <i>Clinical Lymphoma and Myeloma</i> , 2005, 6, 251-252.	1.4	3
44	CD26 Expression Correlates with a Reduced Sensitivity to 2-Deoxycoformycin-Induced Growth Inhibition and Apoptosis in T-Cell Leukemia/Lymphomas. <i>Clinical Cancer Research</i> , 2004, 10, 508-520.	3.2	25
45	CD90/Thy-1 is preferentially expressed on blast cells of high risk acute myeloid leukaemias*. <i>British Journal of Haematology</i> , 2004, 125, 203-212.	1.2	26
46	Analysis of IgVH gene mutations in B-cell chronic lymphocytic leukaemia according to antigen-driven selection identifies subgroups with different prognosis and usage of the canonical somatic hypermutation machinery. <i>British Journal of Haematology</i> , 2004, 126, 29-42.	1.2	54
47	Mutational Status of IgVH Genes Consistent with Antigen-Driven Selection but Not Percent of Mutations Has Prognostic Impact in B-Cell Chronic Lymphocytic Leukemia. <i>Clinical Lymphoma and Myeloma</i> , 2004, 5, 123-126.	2.1	9
48	Clinical significance of soluble p53 protein in B-cell chronic lymphocytic leukemia. <i>Haematologica</i> , 2004, 89, 1468-75.	1.7	18
49	Low frequency of bcl-2 rearrangement in HCV-associated non-Hodgkin's lymphoma tissue. <i>Leukemia</i> , 2003, 17, 1433-1436.	3.3	22
50	5-Aza-2-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach?. <i>Blood</i> , 2003, 101, 4644-4646.	0.6	78
51	Hyaluronan-CD44 interaction hampers migration of osteoclast-like cells by down-regulating MMP-9. <i>Journal of Cell Biology</i> , 2002, 158, 1133-1144.	2.3	83
52	Expression of Functional Interleukin-3 Receptors on Hodgkin and Reed-Sternberg Cells. <i>American Journal of Pathology</i> , 2002, 160, 585-596.	1.9	56
53	CD40L induces proliferation, self-renewal, rescue from apoptosis, and production of cytokines by CD40-expressing AML blasts. <i>Experimental Hematology</i> , 2002, 30, 1283-1292.	0.2	31
54	Co-expression of CD30 ligand and interleukin 4 (IL-4) receptors by acute myeloid leukaemia blasts is associated with the expansion of IL-4-producing CD30+ normal T cells. <i>British Journal of Haematology</i> , 2002, 117, 59-69.	1.2	10

#	ARTICLE	IF	CITATIONS
55	Hodgkin and Reed-Sternberg cells express functional c-kit receptors and interact with primary fibroblasts from Hodgkin's disease-involved lymph nodes through soluble and membrane-bound stem cell factor. <i>British Journal of Haematology</i> , 2002, 118, 1055-1064.	1.2	22
56	A novel bcl-1/JH breakpoint from a patient affected by mantle cell lymphoma extends the major translocation cluster. <i>Journal of Pathology</i> , 2002, 197, 256-263.	2.1	13
57	CD30L up-regulates CD30 and IL-4 expression by T cells. <i>FEBS Letters</i> , 2001, 508, 418-422.	1.3	20
58	In vitro and in vivo effects of 2-â€²-deoxycoformycin (Pentostatin) on tumour cells from human β^2 T-cell malignancies. <i>British Journal of Haematology</i> , 2000, 110, 188-196.	1.2	30
59	Normalizing Complementary DNA by Quantitative Reverse Transcriptase-Polymerase Chain Reaction of β 2-Microglobulin: Molecular Monitoring of Minimal Residual Disease in Acute Promyelocytic Leukemia. <i>Diagnostic Molecular Pathology</i> , 2000, 9, 98-109.	2.1	19
60	CD30 Ligand (CD30L)-Expressing Acute Myeloid Leukemias: A New Model of Paracrine Interactions for the Regulation of Blast Cells Proliferation. <i>Leukemia and Lymphoma</i> , 1999, 35, 21-35.	0.6	11
61	Characterization of anti-CD138 monoclonal antibodies as tools for investigating the molecular polymorphism of syndecan-1 in human lymphoma cells. <i>British Journal of Haematology</i> , 1999, 104, 152-162.	1.2	22
62	The RET receptor tyrosine kinase, but not its specific ligand, GDNF, is preferentially expressed by acute leukaemias of monocytic phenotype and is up-regulated upon differentiation. <i>British Journal of Haematology</i> , 1999, 105, 225-240.	1.2	19
63	Frequent Expression of the Variant CD30 in Human Malignant Myeloid and Lymphoid Neoplasms. <i>American Journal of Pathology</i> , 1999, 155, 2029-2041.	1.9	21
64	Hodgkin's disease: A disorder of dysregulated cellular cross-talk. <i>Biotherapy (Dordrecht)</i> , 1999, 11, 19-21.	0.7	19
65	Differential expression of the RET gene in human acute myeloid leukemia. <i>Annals of Hematology</i> , 1998, 77, 207-210.	0.8	12
66	The role of eosinophils in the pathobiology of Hodgkin's disease. <i>Annals of Oncology</i> , 1997, 8, S89-S96.	0.6	48
67	Competitive reverse-transcriptase PCR: a useful alternative to Northern blotting for quantitative estimation of relative abundances of specific mRNAs in precious samples. <i>Biochemical Journal</i> , 1997, 325, 565-567.	1.7	15
68	Reed-Sternberg Cells of Classical Hodgkin's Disease React With the Plasma Cell-Specific Monoclonal Antibody B-B4 and Express Human Syndecan-1. <i>Blood</i> , 1997, 89, 3787-3794.	0.6	55
69	CD30 Ligand Is Frequently Expressed in Human Hematopoietic Malignancies of Myeloid and Lymphoid Origin. <i>Blood</i> , 1997, 89, 2048-2059.	0.6	110
70	Reed-Sternberg Cells of Classical Hodgkin's Disease React With the Plasma Cell-Specific Monoclonal Antibody B-B4 and Express Human Syndecan-1. <i>Blood</i> , 1997, 89, 3787-3794.	0.6	1